Travere Therapeutics, Inc. (NASDAQ: TVTX)

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company’s lead product, FILSPARI (sparsentan), has received full approval in the United States to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk of disease progression. Travere Therapeutics also advances sparsentan for focal segmental glomerulosclerosis and is developing pegtibatinase for classical homocystinuria. In addition, the commercial portfolio includes Thiola and Thiola EC for cystinuria. The company’s strategy centers on leveraging its rare disease expertise to bring innovative treatments to patients with high unmet medical need.

Travere Therapeutics generates revenue primarily from product sales of its approved therapies and from milestone and royalty payments under licensing agreements. Sales of FILSPARI in the United States and Europe contribute the majority of product revenue, supplemented by sales of Thiola and Thiola EC for cystinuria. The company receives regulatory and market access milestone payments from partners such as CSL Vifor and potential future payments from Chugai related to sparsentan development in Asia. Royalties are paid to Ligand Pharmaceuticals and Bristol Myers Squibb based on net sales of sparsentan. Additionally, the company may earn revenue from future sales of pegtibatinase if it receives regulatory approval for homocystinuria.

Travere Therapeutics holds a differentiated position in the rare kidney disease market as the developer of the only oral, once daily, non immunosuppressive therapy approved for immunoglobulin A nephropathy. Competitors in the IgAN space include Calliditas Therapeutics with Tarpeyo, Vertex Pharmaceuticals with povetacicept, and Novartis with atrasentan, which are either immunosuppressive or target different pathways. In focal segmental glomerulosclerosis, there are currently no FDA approved pharmacologic treatments, giving Travere a potential first mover advantage if sparsentan gains approval. The company’s competitive advantages stem from its orphan drug exclusivities, deep expertise in rare disease clinical development, and a diversified pipeline that includes pegtibatinase for homocystinuria and the established cystinuria franchise.

Travere Therapeutics serves patients with rare kidney and metabolic diseases and collaborates with specialty partners for commercialization. Specific partner names include CSL Vifor, which handles commercialization of sparsentan in Europe and certain additional territories; Chugai, which holds rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan; and Mission Pharmacal, which provides the licence for Thiola and Thiola EC in the United States and Canada. The end user customers are patients treated by nephrologists, urologists, and other healthcare specialists who prescribe the company's therapies.